Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results

Rocket Pharmaceuticals (NASDAQ:RCKT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04, Zacks reports. During the same period last year, the company posted ($0.62) EPS.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock traded up $0.48 on Friday, reaching $5.01. The stock had a trading volume of 6,771,256 shares, compared to its average volume of 2,064,329. Rocket Pharmaceuticals has a 12 month low of $2.19 and a 12 month high of $9.73. The firm has a market capitalization of $542.18 million, a price-to-earnings ratio of -2.49 and a beta of 0.48. The firm’s 50-day moving average is $3.62 and its two-hundred day moving average is $3.44. The company has a quick ratio of 7.30, a current ratio of 7.30 and a debt-to-equity ratio of 0.06.

Insider Buying and Selling

In other news, CEO Gaurav Shah sold 12,279 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the transaction, the chief executive officer directly owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. The trade was a 1.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Martin Wilson sold 12,253 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the sale, the general counsel owned 683,376 shares in the company, valued at approximately $2,261,974.56. This trade represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 29,415 shares of company stock worth $97,398. Company insiders own 24.76% of the company’s stock.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Rocket Pharmaceuticals by 12.6% in the third quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock valued at $22,469,000 after purchasing an additional 769,743 shares during the period. MPM Bioimpact LLC raised its holdings in Rocket Pharmaceuticals by 141.2% in the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock valued at $9,563,000 after acquiring an additional 2,284,816 shares during the period. Millennium Management LLC raised its holdings in Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock valued at $11,639,000 after acquiring an additional 1,221,554 shares during the period. Newtyn Management LLC lifted its position in Rocket Pharmaceuticals by 25.1% during the third quarter. Newtyn Management LLC now owns 2,502,863 shares of the biotechnology company’s stock worth $8,159,000 after acquiring an additional 502,863 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Rocket Pharmaceuticals by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 2,120,269 shares of the biotechnology company’s stock worth $7,443,000 after acquiring an additional 205,715 shares during the period. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RCKT. JPMorgan Chase & Co. lowered shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 18th. Cantor Fitzgerald lifted their price target on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday. Bank of America cut their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Finally, Lifesci Capital raised Rocket Pharmaceuticals to a “strong-buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Rocket Pharmaceuticals has a consensus rating of “Hold” and an average price target of $14.50.

Rocket Pharmaceuticals News Roundup

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded RCKT to a “Strong-Buy” and published a less negative FY2026 EPS forecast of ($1.81), well above the street consensus of ($2.83) — this reduces expected downside and supports investor confidence. Lifesci Capital note / MarketBeat
• Positive Sentiment: Cantor Fitzgerald raised its price target from $8 to $10 and kept an “Overweight” rating — a $10 PT implies roughly 100% upside from the recent price and can prompt momentum buying and coverage flows. Cantor Fitzgerald via Benzinga
• Positive Sentiment: RCKT reported Q4 EPS of ($0.38), beating the ($0.42) consensus and showing an improvement vs. last year’s ($0.62) loss. Management also provided pipeline updates — the narrower loss and progress on programs support the bull case for a clinical-stage biotech. Q4 press release
• Neutral Sentiment: Some outlets report the analyst consensus as an average “Hold” — mixed street views remain, so while upgrades are driving near‑term interest, broader analyst sentiment is still cautious. Analyst consensus report
• Neutral Sentiment: Wall Street Zen revised its stance to “Hold” — another signal of mixed opinions that could limit sustained rallies unless clinical or commercial news follows. Wall Street Zen article

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.